Everett Harris & Co. CA Boosts Position in Henry Schein, Inc. (NASDAQ:HSIC)

Everett Harris & Co. CA grew its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 15.2% during the 3rd quarter, Holdings Channel reports. The fund owned 148,542 shares of the company’s stock after purchasing an additional 19,600 shares during the period. Everett Harris & Co. CA’s holdings in Henry Schein were worth $10,829,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in HSIC. Vanguard Group Inc. lifted its holdings in Henry Schein by 1.7% in the first quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company’s stock valued at $1,165,425,000 after acquiring an additional 260,537 shares during the period. American Century Companies Inc. boosted its holdings in Henry Schein by 3.1% during the second quarter. American Century Companies Inc. now owns 5,484,286 shares of the company’s stock worth $351,543,000 after buying an additional 162,477 shares in the last quarter. Swedbank AB acquired a new stake in Henry Schein during the first quarter valued at $215,998,000. Nuance Investments LLC increased its holdings in Henry Schein by 6.2% in the second quarter. Nuance Investments LLC now owns 1,863,333 shares of the company’s stock valued at $119,440,000 after buying an additional 108,143 shares in the last quarter. Finally, Burgundy Asset Management Ltd. raised its position in shares of Henry Schein by 1.0% in the second quarter. Burgundy Asset Management Ltd. now owns 1,640,379 shares of the company’s stock worth $105,148,000 after acquiring an additional 16,476 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Activity at Henry Schein

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.14% of the company’s stock.

Henry Schein Price Performance

Shares of NASDAQ HSIC traded up $0.72 during mid-day trading on Friday, reaching $72.39. The company’s stock had a trading volume of 688,164 shares, compared to its average volume of 1,335,087. The stock has a 50-day moving average of $70.40 and a two-hundred day moving average of $69.90. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55. The stock has a market capitalization of $9.27 billion, a P/E ratio of 24.46, a P/E/G ratio of 1.98 and a beta of 0.86. Henry Schein, Inc. has a 1-year low of $60.01 and a 1-year high of $82.63.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The company had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.27 billion. During the same quarter in the prior year, the firm earned $1.31 EPS. Henry Schein’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on HSIC shares. Piper Sandler restated an “overweight” rating and set a $86.00 target price on shares of Henry Schein in a research report on Friday, June 21st. JPMorgan Chase & Co. dropped their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. UBS Group reduced their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Baird R W upgraded Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Barrington Research reissued an “outperform” rating and issued a $82.00 price target on shares of Henry Schein in a report on Friday, September 20th. One analyst has rated the stock with a sell rating, six have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $77.50.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.